BioStock: RhoVac’s candidate attacks cancer at its weakest
With its drug candidate RV001, Lund-based drug developer RhoVac is taking a new approach in the fight against metastatic cancer tumours. The company is currently targeting prostate cancer, one of the world’s most common cancers, and achieving a successful proof-of-concept here opens the door to development in other cancers as well. BioStock has taken a closer look at RhoVac’s treatment concept and how it differs from other cancer treatments, something that was also highlighted during World Immunisation Week last week.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se